Catalysts for Institute of Hematology & Blood Diseases Hospital
3 tracked
Apr 30, 2026
phase 1 2 initiation
Institute of Hematology & Blood Diseases Hospital — azacitidine (Phase I/II Trial Initiation)
Onureg
→
Apr 30, 2026
phase 1 2 completion
Institute of Hematology & Blood Diseases Hospital — cyclophosphamide (Phase I/II Trial Completion)
cyclophosphamide
→
RECRUITING
phase readout
NCT07362238: Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
Institute of Hematology & Blood Diseases Hospital
→